How Can Cardiovascular Risk Be Reduced in Kidney Dialysis? :

The experimental IL-6 inhibitor clazakizumab improves key inflammation markers in one study, whereas another shows lower risks with home hemodialysis vs peritoneal dialysis.

Related Keywords

California , United States , Cincinnati , Ohio , Stanford University , Stockholm , Sweden , Solna , Stanford , University Of Cincinnati , Peter Stenvinkel , Glenn Chertow , Silvi Shah , Division Of Nephrology , Division Of Renal Medicine At Karolinska Institutet , Stanford University School Of Medicine , European Renal Association Congress , European Renal Association , Stanford University School , Albumin Improvements Called , Renal Medicine , Karolinska Institutet , Medscape Medical , United States Renal Data System ,